Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists

@article{Andersohn2009CardiacAN,
  title={Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists},
  author={Frank Andersohn and Edeltraut Garbe},
  journal={Movement Disorders},
  year={2009},
  volume={24}
}
There is growing evidence that the ergot‐derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot‐derived dopamine agonists are sparse. Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions. We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US… Expand
Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
TLDR
Cabergoline, typically dosed for the long-term treatment of hyperprolactinemia or acromegaly, appears not to be associated with an increased risk of fibrotic adverse events. Expand
Pulmonary Artery Occlusion and Mediastinal Fibrosis in a Patient on Dopamine Agonist Treatment for Hyperprolactinemia
TLDR
As CT and V/Q scintigraphy findings can occasionally be deceptive, physicians should be particularly aware of differential diagnoses in patients without obvious history of venous thromboembolism that are suspected of having chronic thromBoembolic pulmonary hypertension. Expand
Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia.
TLDR
Although most reports do not show an association between use of dopamine agonists and valvulopathy, caution must be exercised, especially in patients requiring long-term, high-dose medication regimens, Clinicians should recommend the lowest possible doses of dopamine receptors and address the question of echocardiographic monitoring on an individual basis. Expand
Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study.
TLDR
The findings indicated that despite the well known effects of cabergoline on valvular functions, the authors did not observe any alteration in systolic functions, but diastolic functions which was associated with cumulative cabergol dose in patients with Parkinson's disease. Expand
Inflammatory aneurysm of the abdominal aorta in a patient treated with ropinirole
TLDR
A 72-year-old man from moderately advanced Parkinson’s disease is presented who developed inflammatory aneurysm of the abdominal aorta while on long-term treatment with ropinirole, and remains in clinical remission during steroid tapering to a maintenance dose of 10 mg/day. Expand
Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.
TLDR
CAB does not increase the risk of significant cardiac valve regurgitation in prolactinomas after the first 5 years of treatment. Expand
The Role of Serotonin in Singultus: A Review
TLDR
The plausibility of the serotonergic singultus hypothesis is examined against available pharmacokinetic, pharmacodynamic, and clinical data for a number of drugs; beneficial (therapeutic) effects for hiccup are to be expected from serotonin (5-HT) receptor subtype ligands that enhance vagal activity. Expand
Apomorphine - pharmacological properties and clinical trials in Parkinson's disease.
TLDR
Apomorphine is often considered an archetypal dopamine agonist used in the treatment of Parkinson's disease, and when administered as an acute subcutaneous injection, it induces reliable and rapid relief from OFF periods underscoring its utility as a rescue medication. Expand
Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies
TLDR
These consensus guidelines will help to harmonize clinical practice and to standardize and improve care for BH4 deficient patients. Expand
l‐DOPA‐induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?
TLDR
It is proposed here that the significance of inflammation in PD may go beyond the nigral cell death, and the key aims of current PD research ought to be to elucidate the time sequence in which the inflammatory factors act in PD patient brain and the mechanisms by which neuroinflammatory response contributes to the collateral effects of l‐DOPA treatment. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 18 REFERENCES
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease
TLDR
It is suggested that affinity for 5-HT(2B) receptors is routinely tested in future drugs, in the laboratory or in animals, before they are given to patients, to help establish whether and when mitral valve tenting area abnormalities become clinically relevant during chronic treatment. Expand
Fibrosis associated with dopamine agonist therapy in Parkinson's disease.
TLDR
The results indicate, to a certain extent, that the relative risk for onset of dopamine agonist-related fibrotic syndromes is lower particularly for pramipexole and lisuride, which have been available for more years than pramipesxole. Expand
Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: A reader‐blinded monocenter echocardiography study
TLDR
The data suggest that ergot DAs are associated with higher prevalence of VHD compared to non‐ergot DAs and controls, and standard echocardiography seems sufficient to detect VHD in PD patients treated with DAs. Expand
Dopamine agonists and the risk of cardiac-valve regurgitation.
TLDR
Use of the dopamine agonists pergolide and cabergoline was associated with an increased risk of newly diagnosed cardiac-valve regurgitation. Expand
Pleuropulmonary changes induced by ergoline drugs.
TLDR
The outcome was favourable showing slow improvement in all cases following discontinuation of the ergoline, and slight residual pleural thickening was seen in five out of the six cases with pleural involvement. Expand
Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non‐ergot agonists may also not be spared
TLDR
Companion letters have been published in this issue of Movement Disorders: Horowski et al. and Rascol et al., pp 1524–1525. Expand
Pleural fibrosis associated with dihydroergocryptine treatment.
TLDR
After changing the dopamine agonist to the non-ergoline substance pramipexole, marked improvement of the clinical symptoms of PPF occurred, while radiological signs showed only a moderate decrease. Expand
Pleuropulmonary disease associated with dopamine agonist therapy
TLDR
A causal link between ergot‐derived dopamine agonists and pleuropulmonary disease is suggested and similar adverse effects induced by the newer agonists lisuride and cabergoline are reported. Expand
Cabergoline-related severe restrictive mitral regurgitation.
TLDR
The patient had Parkinson's disease that had initially been treated with levodopa, to which cabergoline had been added during the preceding four months, and was notable for increased jugular venous pressure, bilateral rales, and edema in both legs. Expand
Pergolide-Induced Pleuropulmonary Fibrosis
TLDR
Four patients who developed pleural and/or pulmonary fibrosis during treatment with pergolide are reported on and characteristics of 87 cases with one or more symptoms of serosal fibrosis are given. Expand
...
1
2
...